Revisiting: Melanocortin agonists: mechanism and the documented adverse profile posts 31–60
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
Reading a supplier's product description as a marketing document: that is exactly what it is. The hyperbole, the mechanism written as fact, the theoretical benefits stated as established benefits — all of that is marketing. Treat it as such and separate it from evidence where evidence exists.
One more caveat and then I will stop qualifying: the sample selected itself.
Distinguishing three things in the Melanocortin agonists discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the recommendation that gets attached to both.
The honest summary for most of this subcategory: a plausible mechanism, animal data, and first-hand accounts. Saying so is more useful than assembling the accounts into something that reads like evidence.
Stating my assumptions rather than smuggling them in.
PT-141 was developed from the same family with a different receptor profile, and it has a considerably better documented human evidence base than most compounds discussed in this subcategory.
On Melanocortin agonists, the part that usually goes wrong is that the question is asked as though it has one answer. It has a range, and the width of the range is the interesting bit.
If you can post the two or three numbers you are working from, several people here will check the arithmetic rather than argue about the conclusion.
Confirming post #39 from a second method, which matters more than confirming it from a second person.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Taking post #40 at face value and following it one step further.
Dose conversions between related compounds in this subcategory are made far too casually. Structural similarity does not imply potency similarity and frequently does not imply the same receptor profile.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
It is worth stating the boring hypothesis before the interesting one.
Building on post #44 rather than restating it.
Trying to state the Melanocortin agonists position in a way that someone who disagrees would recognise as fair, because I do not think the version in this thread passes that test.
Melanotan II is a non-selective melanocortin agonist, which is why its effects are not confined to pigmentation. The non-selectivity is the mechanism and not a side issue.
Not the answer, but possibly the question that gets there.
An honest declaration on Melanocortin agonists: I have a prior here and it is strong enough that you should weight what I say downward. Stating it rather than hiding it.
Following this. I have the same question and no better information than the first post.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Second-hand, so weight it accordingly.
Solubility varies far more across this subcategory than within the incretins. A compound that needs a specific diluent or a specific pH is not being difficult; it has a solubility profile and the supplier should state it.
Reading a supplier's product description as a marketing document: that is exactly what it is. The hyperbole, the mechanism written as fact, the theoretical benefits stated as established benefits — all of that is marketing. Treat it as such and separate it from evidence where evidence exists.
Post #50 describes the usual case. This is about the unusual one.
Adding what did not work for me on Melanocortin agonists, since the failures never get written up and they are half the useful information.
Melanocortin agonists has a well-known answer and a correct answer, and the interesting work is establishing that they are the same. Nobody has done that here yet.
AOD-9604 is a fragment of human growth hormone and has been discussed as a potential weight-loss agent based on theoretical mechanism. The fragment hypothesis — that the fragment retains a specific property of the intact hormone — is not settled for this compound.
I would treat that as a working assumption and revisit it.
Building on post #53 rather than restating it.
Second-hand on Melanocortin agonists, so weight it accordingly — someone whose method I trust told me this and I have not verified it myself.
Something worth flagging about Melanocortin agonists: the strongest-sounding claims in this thread are the ones with no source attached, which is the usual pattern and not a coincidence.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Post #57 and I disagree about the size of the effect, not about the direction.
Two sentences on Melanocortin agonists and then I will stop, because the rest is speculation and the thread is better without mine.
What is documented is narrow. What is inferred from it is broad. The gap between them is where every argument here lives.